Author: admin

Ethics and Social Science  – a community in partnership

Last month the Ethics and Social Science Genomics England Clinical Interpretation Partnership (GeCIP) held its first national community meeting in London. Alev Sen, an ESRC-funded PhD Fellow at Genomics England, describes some of the day’s highlights.

It’s not that often that over 100 leading ethics and social science researchers in the field of genomics come together with patients and families, clinicians, scientists, and policy-makers from across the UK to look at how we can contribute to world-class research and inform the future of genomics.  It was a lively and informative day, with many more engaging online via social media.

The future of genomics

Chief Medical Officer Professor Dame Sally Davies began her opening keynote by considering the progress that had been made on realising the ‘genomic dream’ of making genomics available to more NHS patients – something she had first outlined in her 2016 annual report Generation Genome. She described the setting up of the National Genomics Board by the Secretary of State for Health to support this vision, NHS England’s programme in partnership with Genomics England to develop a National Genomic Medicine Service, the recent Life Sciences Sector Deal between government and the life sciences industry, and the current review for the renewal of the Concordat and Moratorium on Genetics and Insurance between the government and the Association of British Insurers (ABI).

Dame Sally discussed ethical and societal considerations as key to the future of genomics in UK healthcare, highlighting the dedicated chapters in Generation Genome on the social contact for genomics in the NHS and genetic information and insurance. She finished by urging us to build on  learning from the 100 000 Genomes Project and the NHS Genomic Medicine Centres (GMCs) as a basis for internationally recognised and respected ethical approaches.

Research in the 100,000 Genomes Project

Genomics England’s Chief Scientist Professor Mark Caulfield followed with an update on the 100,000 Genomes Project. He gave a preview of the Genomics England Research Environment – the IT research platform housing genomes and clinical data from the project. In between recently reaching the 50,000 whole human genome sequences landmark, Mark highlighted cases of participants receiving diagnosis and treatment options as a result of taking part in the project.

Mark discussed opportunities for research through the GeCIP structure, including scope for partnership working between world-leading researchers, clinical academics and industry, and controlled access to genomic and clinical data and patients and family participants following review and approval.

GeCIP conversations

Possibilities for the Ethics and Social Science GeCIP were explored in a series of conversations with key research partners and stakeholders held by members of the GeCIP and chaired by Professor Michael Parker.

Talking to Dr Pauline McCormack, Ms Hannah Podd and Ms Shelley Simmonds, participants in the 100,000 Genomes Project, gave personal and frank accounts which were both insightful and illuminating.

Dr Saskia Sanderson talked with the Wellcome Sanger Institute’s Dr Matthew Hurles about interdisciplinary approaches to translating genomics into patient benefits.

Finally, Professor Richard Ashcroft and Mr Hugh Whittall, Director of the Nuffield Council on Bioethics, discussed bringing academic experience and evidence to bear on policy problems for genomic medicine and science.

These discussions led on to presentations on research already underway in the Ethics and Social Science GeCIP.

  • In their keynote, Professor Anneke Lucassen and Professor Bobbie Farsides presented their new research on ethical preparedness in genomic medicine (the EPPiGEN project) supported by a Wellcome Trust Collaborative award. Anneke and Bobbie discussed the need for their research in the context of genomic medicine presenting new and challenging interactions for healthcare professionals and patients and planned roll out across the NHS. They had built on learning and collaboration in the Ethics and Social Science GeCIP, from a national forum for professionals involved in the delivery of the 100 000 Genomes Project and from ethics research in NHS GMCs, as part of the journey to developing their study.
  • Dr Felicity Boardman described the social and ethical implications of pre-conception genetic screening for conditions of uncertain or variable prognosis
  • Ms Mavis Machirori presented work on the implications for future genomic services of BME women’s decision-making for risk reduction after BRCA testing
  • Dr Celine Lewis described young people’s experience of taking part in the 100,000 Genomes Project, and
  • Dr Ingrid Slade discussed clinical genomic medicine and the need for a public health ethics account.

Opportunities for the future

The day’s final discussion explored the question of ‘what next’ for the Ethics and Social Science GeCIP. The panel discussed the scope for research using diverse methodologies from large-scale cohort studies to in-depth scholarly work; informing the decisions of policy-makers, in particular through research on the experiences and views of patients, publics and practitioners; and developing fit-for-purpose patient and public involvement approaches as genomics moves further into the NHS. The panel agreed that there were wide-ranging possibilities for future research facilitated through the GeCIP with potential to contribute academic value and make a difference to the future of genomic medicine and science.

This first national meeting of the Ethics and Social Science GeCIP was brought to a close by Professor Michael Parker expressing the need to build on engagement and momentum from the event. He called for continued ambition for research on the ethical aspects and social implications of genomics, highlighting the scale of transformation for UK healthcare.

Read more

Rare Disease Day – embedding patient experience at the heart of rare disease research

As the world marks Rare Disease Day on 28 February, Genomics England explores patient and clinical perspectives of rare disease.

In this blog we hear from Rebecca Middleton − taking part in the 100,000 Genomes project’s rare disease programme and Vice Chair of the Project’s Participant Panel.

In an accompanying blog we hear from Dr Richard Scott, Genomics England’s Clinical Lead for Rare Disease. While coming at the rare disease experience from different directions, they share the idea of progress, challenges – and hope.

Embedding patient experience at the heart of rare disease research

“I was sat drinking tea at my uncle’s wake nearly five years ago when the penny finally dropped. My maternal uncle had died due to a ruptured aortic aneurysm a week earlier; he was 62. Five years earlier my mother had died at the age of 59 of a brain haemorrhage due to a ruptured cerebral aneurysm. Talking to my relatives at the wake, my cousins and I started to pull the pieces together of the most unfortunate puzzle. We realised that a further two relatives had died of complications due to aneurysms, both aortic and cerebral, including my maternal grandmother.

We all fell silent as we realised that an unfortunate coincidence was, in fact, looking like an unfortunate flaw in our genes. After further research and talking to many experts in the field, I finally underwent a brain scan in 2014 to discover that I too had a brain aneurysm and the genetic flaw continued down our family line.

My small aneurysm is in a difficult position which means it can’t be treated without big risks, so I undergo regular monitoring and learn to live with the anxiety it brings. Along the way, I was diagnosed with familial aneurysm syndrome, a broad-brush label for an unknown fault in my genes.

Since this discovery, I have been on a remarkable journey. After existing NHS genetic testing didn’t find the answers I was looking for, I was recruited onto the 100,000 Genomes Project, became a participant on my local project delivery board in Leicester and Vice-Chair of the national 100,000 Genomes Project Participants Panel.

I am incredibly proud to sit on the local and national panels, which are at the heart of Genomics England. The Participants Panel is made up of participants from both the rare disease and cancer parts of the project and works incredibly hard to ensure our interests are represented and our valuable data used responsibly by the medical and research community.

Rare disease is complex and so is living with it. There are over 6,000 rare diseases, often presenting themselves in their own unique way. Today, one in 17 of us is living with a rare disease and each of us has had a very different and difficult journey to the door of our genetic counsellor or hospital consultant.

Rare disease day this year throws a spotlight on the patient’s involvement in research. A place where we should naturally be. It’s our ‘uniqueness’, experience and knowledge of our own disease that makes us the best placed experts to work with researchers to move medicine and understanding forward.

And that means more than being told about research, but rather being an active player in how it is developed, carried out and reported. As technology and the optimisation of big data progresses, it becomes critically important that we, as patients, work with researchers and the medical community to design research that answers our critical questions. We should be seen more than a sum of our symptoms; our voices not lost in the 3.2 billion letters of our genome.

I’m pleased to say that the national Participants Panel of the pioneering 100,000 Genomes Project reports straight to the project’s governance board. We have a loud voice at the top table. It is ground-breaking patient involvement for a ground-breaking project. We are not ‘token’ patients but have helped deliver real change for the benefits of patients and their carers already, with the support of the project team.

As the NHS aims to bring genomics from the side-lines of medicine to the mainstream by the end of the year, there is a real opportunity and appetite for meaningful patient involvement at every level of the service.

For myself and many others, research means hope. As we often have little control over our disease, it is that hope that keeps us searching for answers for ourselves and our families – or in my case for the sake of my two beautiful, young daughters. By active and effective involvement of patients in rare disease research and service design, we too can move forward from the side-lines and be central to finding future cures, treatments and better care for families. Through involvement, we become an asset as well as a patient. Let’s make that hope a reality.”

Rebecca Middleton is Vice Chair of the 100,000 Genomes Project Participant Panel.

Rare Disease Day – rare diseases aren’t rare

In this blog Dr Richard Scott talks about the long path to diagnosis for many people with rare diseases, and the challenge of raising awareness amongst the public and healthcare professionals.

As the world marks Rare Disease Day on 28 February, Genomics England explores patient and clinical perspectives of rare disease. In an accompanying blog we hear from Rebecca Middleton on how through the 100,000 Genomes Project, patient experience is being placed at the heart of rare disease research. While coming at the rare disease experience from different directions, they share the idea of progress, challenges – and hope.

Rare diseases aren’t rare – so it’s important we focus on them

Rare Disease Day was first launched 10 years ago by EURODIS − an alliance of patient-driven organisations in Europe. It’s now a worldwide phenomenon.

Why the focus on rare diseases you ask? Are there not more mainstream problems to focus on? Well, the name is misleading. Rare diseases are individually rare − by definition − affecting less than 1 in 2,000 people. But there are an estimated 6,000 or so of them, meaning that they are collectively common: an estimated 1 in 17 of us is affected.

Rarity brings with it problems, but they don’t stop there. At least half of rare disease affect children. And their impact is often severe – sadly, 30% of those with rare disease die before their 5th birthday. The impact on health and normal life is often substantial, even in those less severely affected. The diseases are typically lifelong and often affect multiple organ systems of the body.

In the ten years since the launch of Rare Disease Day, there has been much progress. There has been increasing recognition of the importance of rare diseases and increasing focus of governments and health systems. In the UK, the Department of Health issued a Rare Diseases Strategy in 2013 and will today issue an update on progress.

The long path to diagnosis – the so called ‘diagnostic odyssey’ – has been a major area of focus. It needs to be. Surveys show that it takes an average of five years to receive a diagnosis and 40% of patients are misdiagnosed.

Most rare diseases are thought to have genetic cause and the great advances in genomics in recent years are helping. Now it can cost as little as $1,000 to sequence a whole genome, although that doesn’t include the costs of interpreting the data and generating a clinical report. Other forms of genetic testing are cheaper too.

In the UK we are lucky to have access to whole genome sequencing for rare disease patients on a research basis through the 100,000 Genomes Project, on which I work. We’ve now reached the half way mark in the project, having sequenced over 50,000 genomes, and are working closely with NHS England to develop the systems that will allow genome sequencing to enter mainstream diagnostic use. This will again place us right at the forefront of rare disease genomics − but that shouldn’t make us complacent.

Even with the very best technologies available, rare disease diagnostics remain hard. In many settings, the majority of patients remain undiagnosed. Our knowledge is advancing rapidly, but is still far from complete. We all carry hundreds of rare genetic variants and it can be challenging to spot the variant that is the cause of a person’s rare disease, even if it’s in a well-known gene.

In the UK we have a long history of close work between genomics laboratories and clinicians. This new era of genomics will require even closer laboratory-clinical working to ensure we fully harness the extraordinary potential of the technologies we now have in our hands.

In the context of these great scientific advances, some of the biggest challenges we face may seem prosaic. Simply recognising that someone might have a rare disease is often challenging. How do we make the public and primary care and front line mainstream medical teams aware of these individually rare conditions?

By raising the profile of rare diseases as a whole, efforts such as Rare Disease Day are already beginning to have an effect. Broader education of the medical workforce about genomics is also helping. But there’s a long way to go and other approaches will be necessary. Increasing integration of genomics services with mainstream specialties is vital. With increasing use of electronic health care systems, there are also great potential benefits from building systems that highlight the need to consider rare disease or refer for a specialist opinion.

But rare disease care is about far more than just testing and ending the diagnostic odyssey. Coordination of the complex care of rare disease patients is often challenging, but is essential for high quality care and can bring considerable psychosocial benefits and cost savings. Currently, many patients and families bear the burden of the task. This is an area in need of greater investment.

With most rare diseases hard to treat, even when a diagnosis is made, research must be at the core of the care we offer. And with the number of people with each disease so small, patients’ wishes to share their data broadly must be heeded.

While we should be grateful that there is an increasing patient voice bringing us events such as Rare Disease Day, the drive of patient groups shouldn’t be taken for granted. You don’t need to hear many stories of patient-led research initiatives to realise that the onus is on the medical and pharmaceutical communities to keep pace with the endeavour of those affected with rare disease.”

Dr Richard Scott is Genomics England’s Clinical Lead for Rare Disease

UK leads the world as 100,000 Genomes Project hits the 50,000 genomes landmark to transform NHS patient care

The Department of Health and Social Care, NHS England and Genomics England today announced reaching the 50,000 whole human genome sequences landmark within the 100,000 Genomes Project.

It is a milestone that sets the UK on track to fully realise the potential of genomic medicine, deliver better care for patients and establish the UK as the global ‘go to’ destination in the fast emerging genomics sector.

Genomics England was established in 2013 as a wholly owned company of the Department of Health and Social Care by the Secretary of State, Jeremy Hunt. It is tasked with the delivery of the groundbreaking 100,000 Genomes Project, which is sequencing 100,000 genomes from 70,000 people, focused on patients with rare diseases, their families, and patients with cancer.

In stimulating genomic research and discovery, Genomics England aims to improve patient care and establish the UK as the centre of the global genomics industry.

Achieving the 50,000 genomes landmark has only been made possible through the generous participation of tens of thousands of patients and their families – taking part in a Project at the edge of known science. Staff in NHS Genomic Medicine Centres (GMCs), as well as those in Northern Ireland, Scotland and Wales, have worked tirelessly to not only deliver the Project, but in many cases, also pioneered totally new systems, processes and procedures to ensure that genomic medicine can become part of routine NHS care.

The project is already changing the lives of patients with a rare disease – often providing diagnoses for the first time after years of uncertainty and distress (known as the diagnostic odyssey), as well as working towards reducing costs to health and social care budgets. In cancer, significant progress has been made in tackling the global challenge of extracting of DNA of sufficient quality for whole genome sequencing – leading to significant redesign of tissue handling in the NHS.

The scope and scale of the 100,000 Genomes Project, unparalleled anywhere else in the world, has been made possible through the UK’s unique asset − its National Health Service. The NHS, as the single biggest integrated healthcare system in the world, is able to link lifelong healthcare information with whole genome sequencing data. It is a combination that brings benefit to patients whilst also demonstrating the UK’s competitive advantage in enhancing understanding of diseases, and developing products for earlier detection and treatment.

Health Secretary Jeremy Hunt said:

“This incredible achievement shows once again why the UK is a world leader in genomic medicine.
“We’re backing our world-leading scientists and clinicians in the NHS to push the boundaries of modern science and embrace new technology – using data to transform the lives of patients and families through quicker diagnoses and personalised treatments.
“It is testimony to the hard work of the clinicians and scientists across the NHS and volunteers for the project that we can continue to harness the very best of the NHS and remain at the forefront of this pioneering field.”

Genomics England Executive Chair, Sir John Chisholm, said:

The 100,000 Genomes Project was a stunningly ambitious project when announced by the (then) Department of Health five years ago. Since then Genomics England and NHS England (now joined by Scotland, Northern, Ireland and Wales), working with a huge number of ground-breaking partnerships, have built the infrastructure and protocols to deliver health-enhancing diagnostics from consented patients with undiagnosed rare genetic disease and common cancers, while at the same time enabling their data (in de-identified form) to provide the basis for research leading to improved therapies and treatments. Having built the platform and reached the 50,000 halfway point we are now able to operate at a scale to complete the target by the end of 2018.

Professor Sue Hill OBE, Chief Scientific Officer for England and Senior Responsible Officer for Genomics at NHS England, said:

This is an important milestone for the project and has only been possible because of the contribution and commitment of the participants in the project and their families.
“The milestone also marks how healthcare professionals from across the NHS have come together to transform care for the future, demonstrating how this technology can be utilised as part of routine care to improve patient lives and keep the NHS a world-leader in this important area of medicine. Working together patients and professionals have achieved so much and I would like to say a personal thank you to each and every one for playing their part.
“We are on track to complete recruitment to the Project this Autumn and, from then, the use of these cutting-edge genomic technologies will be embedded in the NHS through the new Genomic Medicine Service offering real benefits to patients and healthcare delivery.

Francis deSouza, President and CEO of lllumina (the 100,000 Genomes Project’s sequencing partner), said:

This important milestone in our partnership with Genomics England marks a significant step towards delivering whole genome sequencing at scale into the NHS and provides physicians with the data to make diagnoses based on a patient’s genome that will lead to better health outcomes.

Wales joins the 100,000 Genomes Project

Wales has joined the 100,000 Genomes Project, the Welsh Government announced today.  The project, now a UK-wide initiative, seeks to transform patient care, encourage genomic discovery and drive a thriving genomics sector.

In an agreement between Cardiff and Vale University Health Board (CVUHB), Cardiff University and Genomics England (the company leading the Project across the UK), 420 whole genome sequences (WGS) have been commissioned for patients with rare diseases and their families, in Wales.

The 100,000 Genomes Project aims to sequence 100,000 genomes from 70,000 people with rare diseases and their families, as well as those with cancer. To date, almost 50,000 whole genomes have been sequenced, with the ultimate 100,000 WGS milestone due to be reached by the end of 2018.

Welsh rare disease patients and their families, who choose to participate in the 100,000 Genomes Project, may be provided with a diagnosis and spared years of uncertainty and distress (often known as the diagnostic odyssey). With more precise and rapid diagnosis, there is also the potential to reduce pressure on Welsh health and social care budgets.

Today’s announcement brings together the Welsh Government, AWMGS, CVUHB, Cardiff University, the Wales Gene Park, the Medical Research Council (MRC) and Genomics England to establish the first Genomic Medicine Centre (GMC) in Wales. This joins 13 other NHS GMCs in England, the Northern Ireland GMC and the Scottish Genomes Project. The Wales GMC, based at the University Hospital of Wales site in Cardiff, has been supported by the Welsh Government and the MRC, which contributed £2.4 million and £1 million in funding respectively.

Participation in the 100,000 Genomes Project supports the Welsh Government’s ‘Genomics for Precision Medicine Strategy’, which sets ambitious goals for genomic medicine, including the development of:

  • internationally recognised medical and public health genetics services;
  • internationally recognised research in genomics and excellent platforms for precision medicine;
  • new strategic partnerships in genomics and precision medicine; and
  • the NHS and research workforce to underpin the delivery of genomic medicine.

Professor Mark Caulfield, Genomics England Chief Scientist, said:

“Genomics is transforming healthcare and our ability to diagnose and treat rare disease and cancer. In joining the rare disease programme of the 100,000 Genomes Project, Wales has placed itself at the centre of genomic medicine revolution that will greatly improve patient outcomes, encourage exciting new discoveries and drive a world leading genomics industry.”

Health Secretary, Vaughan Gething said:

“We are delighted that Wales has joined the 100,000 Genomes Project. The collaboration with Genomics England will enable patients with rare diseases in Wales to benefit from this exciting and transformational project, with the potential to bring quicker and more accurate diagnoses.”

The Director of the Division of Cancer and Genetics at Cardiff University School of Medicine and Honorary Consultant in Clinical Genetics with Cardiff and Vale University Health Board, Professor Julian Sampson, who leads the project in Wales, said:

“Patients in Wales with rare conditions in whom routine testing failed to make a diagnosis now have a chance to access the most comprehensive genetic test available; sequencing of their entire genome. This will increase the chances of achieving a specific diagnosis to inform their health care. Wales’ participation in this UK-wide project is helping to establish genomic medicine in the NHS.

“This will have far-reaching benefits for the understanding, diagnosis and treatment of many conditions.”

Chief Scientific Advisor for Health, Dr Rob Orford said:

“A key component of the Welsh Government’s Genomics for Precision Medicine Strategy is the creation of the collaborative Genomic Medicine Centre (GMC). The GMC will act as a springboard for the translation of cutting edge genomic research into better services and treatments for people of Wales.”

Dr Nathan Richardson, head of molecular and cellular medicine at the MRC, said:

“We welcome these very exciting developments that will help to establish a strong Wales-England partnership, which brings together patient genomes to enhance our ability to tackle the biggest challenges in understanding the role of human genetics in disease.  We are excited by the prospects of people in Wales – and throughout the UK – who are affected by a rare condition and will benefit hugely from a new era of genomic medicine.”

The 100,000 Genomes Project is now a UK-wide initiative with recruiting centers in Northern Ireland, Scotland and Wales

More information:

Verge Genomics joins the Discovery Forum

Verge Genomics joins the Discovery Forum to transform pioneering research into frontline patient treatments.

Genomics England and Verge Genomics, a leading artificial intelligence therapeutics company, announced today that Verge will join Genomics England’s Discovery Forum industry partnership. The partnership aims to translate groundbreaking research into innovative treatments, and ultimately patient benefit, as rapidly as possible.

The Discovery Forum provides an engagement platform for industry partners, academia, the NHS, and the wider genomics community. More than 30 of the world’s leading genomics companies come together within the Forum to work in a pre-competitive environment with access to whole genome sequences from the 100,000 Genomes Project.

Verge brings additional strengths to the Discovery Forum, with its extensive and growing network of data partnerships. In late 2017, Verge announced two public-private partnerships with a dozen academic and national institutions, leading to the creation one of the world’s largest collections of ALS and Parkinson’s Disease patient data. In January 2018, Verge announced a collaboration with Datavant, a Roivant Sciences-backed company focused on data aggregation to improve clinical trials, to unlock the value of one of the world’s most extensive collections of patient genomes and clinical data.

Alice Zhang, Verge Genomics CEO, said:

“Verge is committed to integrating datasets held by industry, academic and government partners, because we believe that shared understanding will drive ever more effective treatments for patients around the world. We are honored to share this mission with Genomics England.”

Professor Joanne Hackett, Genomics England Chief Commercial Officer, said:

“Industrial partnership is critical to unlocking the true potential of genomic medicine. In combining the unique scale and richness of the Genomics England dataset with the expertise and relentless innovation of companies such as Verge, we can rapidly turn pioneering research into frontline patient care.”


Genomics England and Inserm partnership strengthens UK-French cooperation in genomic medicine

As part of the UK-French summit held in Sandhurst yesterday (18 January 2018), the UK and French Governments have announced enhanced cooperation between Genomics England and the French ‘Médecine Génomique 2025’ project.

The Strategic Genomic Medicine Partnership marks a strengthening of the existing relationship between Genomics England and the French National Institute of Health and Medical Research (Inserm). Formalising the agreement, senior representatives of both organisations signed a letter of intent for a Memorandum of Understanding (MoU).

The UK and France will combine our shared national attributes by co-funding shared analysis of new technologies to accelerate genomic medicine and research collaboration, ultimately improving the care of patients with cancer and rare diseases.

L-R: Matt Hancock MP, Sir John Chisholm, Yves Levy and Brune Poirson, at the UK-France Summit 2018.

Genomics England Executive Chairman, Sir John Chisholm, said:
“The Strategic Partnership announced today sees two global pioneers combining know-how to realise the full potential of genomic medicine. Genomics England and Inserm will work together more closely than ever before – signalling our joint ambition to lead the world in genomic discovery, develop more effective treatments and drive economic growth in the sector.”

Genomics England Chief Scientist, Professor Mark Caulfield, said:
“Today’s agreement ensures that the UK and France continue to set the pace in global genomics. Both of our nations are on the verge of introducing genomic medicine into mainstream health services and this enhanced cooperation will allow us to set new and lasting global standards, share learning and, ultimately, deliver the best possible care to our patients.”

Genomics England adopts Edico Genome’s DRAGEN Bio-IT Platform

Genomics England adopts Edico Genome’s DRAGEN Bio-IT Platform to increase accuracy, consistency of next-generation sequencing analysis

Today (8 January 2018) at the annual J.P. Morgan Healthcare Conference, Edico Genome and Genomics England announced a new partnership to strengthen the accuracy and consistency of next-generation sequencing data analysis in Genomics England’s Rare Disease Pilot.

The partnership will further support Genomics England’s 2018 initiative to making next-generation sequencing (NGS) the standard of care across the UK’s National Health Service in 2018. Specifically, the partnership will focus on the analysis pipeline − improving alignment and variant calling in whole genome sequencing data. Genomics England selected DRAGEN for its industry leading accuracy and speed, enabling the organisation to accelerate analysis of large clinical genomic datasets.

“Working with Edico Genome, Genomics England moves one step closer to reaching genomic medicine’s full potential, and improving the efficiency of whole genome analysis to help diagnose rare diseases,” said Joanne Hackett, chief commercial officer at Genomics England. “This partnership demonstrates our commitment to harnessing the most innovative technologies in the world to maximise patient benefit.”

Genomics England is currently using DRAGEN to re-process 5,000 whole human genomes from individuals with rare diseases. These genomes were originally mapped and aligned on reference genome GRCh37, but an updated human reference genome has since been released, GRCh38, which offers increased accuracy and consistency of results. These reprocessed datasets will be provided to pharma and industry partners for additional analysis through the Discovery Forum, a platform for collaboration and engagement between Genomics England, industry partners, academia, the NHS, and the wider UK genomics landscape. In conjunction with the announcement, Edico Genome has joined Discovery Forum.

“Genomics England is truly paving the way for the widespread integration of whole-genome sequencing on a population scale, bringing the future of personalized medicine into the now for individuals across the U.K.,” said Pieter van Rooyen, Ph.D., president and chief executive officer at Edico Genome. “Our bioinformatics and engineering teams are committed to pushing the envelope in terms of accuracy, sensitivity, speeds and scalability to ensure the highest level of personalized care can be delivered in a timely, cost effective and economical manner. We are honored to be able to assist in such an important undertaking – helping diagnose rare diseases — and look forward to bringing further optimizations and new pipelines to customers in 2018.”

By leveraging field programmable gate arrays (FPGAs), DRAGEN provides outputs almost instantaneously and processes clinical grade genomic data at record-breaking speeds. To ensure precise results, all DRAGEN pipelines feature validated algorithms for enhanced accuracy. DRAGEN can be implemented onsite, in the Cloud, or through a blended hybrid-cloud solution.

Edico Genome

Genomics England appoints two new Non-Executive Directors to its Board – to build strategic, medical and commercial strength

Genomics England has announced the appointment of two new Non-Executive members to its Board. Sir Ron Kerr and Keith Stewart bring a wealth of senior scientific, commercial and managerial experience to Genomics England − providing effective support for the strategic and operational leadership of the organisation.

Genomics England’s new Non-Executive Directors bring highly relevant professional expertise and the ability to engage with stakeholders at every level. They are tasked to ensure the on-going pace, innovation and impact of Genomics England’s pioneering work, helping to plan for the future as it progresses beyond the 100,000 Genomes Project:

Sir Ron Kerr

  • Sir Ron Kerr is currently: a Special Adviser to the Board at Guy’s and St Thomas’ NHS Foundation Trust – with a particular focus on commercial issues; Non-Executive Chair of the Bristol, North Somerset and South Gloucestershire Sustainability and Transformation Partnership (STP); Member, Board of Trustees, University of Bristol; and Member, Board of Trustees of the Guy’s and St Thomas’ Charity. His career spans 40 years – including CEO at the National Care Standards Commission and senior leadership roles across the NHS. Sir Ron is married with three children and was knighted in 2011 for services to the NHS.

Keith Stewart

  • Keith Stewart brings an internationally recognised reputation as a leader in the field of genomics. He is currently: Professor of Medicine at the Mayo Clinic College of Medicine and Science (US); Consultant – Division of Hematology/Oncology, Department of Internal Medicine (Mayo Clinic); Vasek and Anna Maria Polak Professor of Cancer Research (Mayo Clinic); Carlson and Nelson Endowed Director – Center for Individualized Medicine (Mayo Clinic); and Consultant – Department of Clinical Genomics (Mayo Clinic). Keith brings a focus on the clinical applications of genomics, sits on a number of scientific advisory boards and has considerable interest in business development activities – setting up two biotech start-ups and holding a number of patents.

Genomics England Executive Chair, Sir John Chisholm, said:

“Sir Ron Kerr and Keith Stewart join Genomics England at a critical moment. Between them they bring deep experience − of the NHS, cutting-edge genomic medicine and commercial opportunity. Their appointment to the Genomics England Board gives us invaluable insight – both as the NHS is on the cusp of introducing the world’s first genomic medicine service and we work to make the UK the global centre of genomics research, innovation and investment.” 

Sir Ron Kerr said:

“As someone who believes fundamentally in the value and potential of the NHS, I am delighted to join Genomics England.  As a Non-Executive Director I hope I can provide some helpful insight and advice that will help to drive true transformation – harnessing that power of genomic medicine for the benefit of patients in the UK and around the world.”

Keith Stewart said:

“Genomics England is an acknowledged global leader in the field of genomic medicine and I am excited by its potential. I will use my experience in translating genomic medicine in the clinic to help this groundbreaking organisation develop and grow ¬– creating new opportunities for patients, the NHS and the UK economy.”

Genomics England welcomes the UK Life Sciences Sector Deal

In response to yesterday’s Life Sciences Sector Deal announcement from the UK government, Sir John Chisholm, Executive Chair of Genomics England said:

“I warmly welcome the UK Life Sciences Sector Deal announced on 6 December – and congratulate Sir John Bell and all of those who have created a transformative roadmap for Life Sciences in the UK.

From the outset, Genomics England has worked to translate the UK’s world leading genomic research into a vibrant UK genomics industry. The Life Sciences Sector Deal recognises and builds on the progress that Genomics England has made in aligning pioneering science with the needs of industry to make the UK the global centre of genomics research, discovery and investment.

The Life Sciences Sector Deal represents a bold ‘green light’ from Government – placing genomic discovery at the heart of the Life Sciences. We are committed to seizing this once in a generation opportunity – furthering our deep industry partnerships to help transform the NHS, bring benefit to patients and drive UK economic growth.”

View our Industry Partnerships pages

1 2 3 4 8